IMMUNE 3DŽ Expands Platform into New Disease Areas and Enters into Drug Discovery

Wednesday, May 15, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

The company will apply its proprietary ex vivo platform and human cell lines to discover and validate targets with broad spectrum therapeutic applications

ROCKVILLE, Md., May 14, 2019 /PRNewswire-PRWeb/ -- IMMUNE 3DŽ, a privately held biotechnology company, announced today

an expansion of their business strategy beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, matched autologous human T cell and tumor cell lines for IO discovery efforts.

IMMUNE 3DŽ's proprietary platform aims to study factors that affect immune migration under complex physiological conditions. The company utilizes the platform in areas of drug target discovery, characterization, biomarker identification and drug delivery testing.

"The increase in preclinical research and development spending has steered biopharmaceutical companies towards finding cost-effective alternatives beyond traditional in vivo models," said Vik Subbu, Founder and CEO of IMMUNE 3DŽ. "This has paved the way for ex vivo platforms such as IMMUNE 3DŽ to be used across areas of preclinical studies and translational drug development."

"IMMUNE 3DŽ provides unique insights into the tumor immune-microenvironment. Importantly, this platform can assess the efficacy of a wide variety of therapeutic approaches beyond immune checkpoints including the evaluation of CAR-T therapies in solid tumors," said Dr. Tonya Webb, Associate Professor of Microbiology and Immunology, at the University of Maryland, Baltimore and scientific advisor to IMMUNE 3DŽ.

IMMUNE 3DŽ aims to build on its extensive know-how and intellectual property to develop proprietary 3D models across broad immune-mediated diseases. The company has profiled targets that facilitate immune migration using its proprietary human T cell and tumor cell lines. These targets have the potential to serve as novel therapies across a variety of human disorders such as cancer, autoimmunity and infectious diseases.

About IMMUNE 3DŽ IMMUNE 3DŽ's proprietary platform, provides a unique and powerful tool to interrogate immunobiology of diseases. The Company's mission is to shift the paradigm towards a wider use of 3D cultures in translational research while accelerating much needed drug candidates into the clinic. The company has assembled a network of key opinion leaders, academic partnerships, board members and industry scientists to advance its platform. http://www.immune3d.com

 

SOURCE Immune 3D



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store